'Exciting Era' Underway

San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.

Related Videos
Related Content

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.